CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.
暂无分享,去创建一个
David A. Lustig | S. Kerwar | Xiaofen Li | K. Shenk | P. Ibrahim | D. Zeng | N. Chu | D. Soohoo | K. Leung | J. Zablocki | D. Koltun | Jia Hao | B. Jiang | R. Natero | T. Marquart | Yuan Li | K. Rehder | E. Elzein | Marie Nguyen | Victoria Y Maydanik
[1] D. Channe Gowda,et al. Facile Transfer Hydrogenation of Azo Compounds to Hydrazo Compounds and Anilines by Using Raney Nickel and Hydrazinium Monoformate , 2004 .
[2] David A. Lustig,et al. New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties. , 2004, Bioorganic & medicinal chemistry letters.
[3] S. Kerwar,et al. Novel inhibitors of fatty acid oxidation as potential metabolic modulators. , 2004, Bioorganic & medicinal chemistry letters.
[4] J. Zablocki,et al. Microwave‐Assisted One‐Step Synthesis of Substituted 2‐Chloromethyl‐1,3,4‐oxadiazoles , 2004 .
[5] Zhihe Li,et al. Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF). , 2004, Bioorganic & medicinal chemistry letters.
[6] L. Belardinelli,et al. Conditional-dependent effects of CVT-4325, a novel fatty acid oxidation inhibitor, on palmitate utilization , 2003 .
[7] J. Hill,et al. Role of Metabolically Active Drugs in the Management of Ischemic Heart Disease , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[8] R. Miller,et al. Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist. , 2000, Bioorganic & medicinal chemistry letters.
[9] C. Strader,et al. Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents. , 2000, Bioorganic & medicinal chemistry letters.
[10] L. Terenius,et al. Design, synthesis, and evaluation of Phe-Gly mimetics: heterocyclic building blocks for pseudopeptides. , 1999, Journal of medicinal chemistry.
[11] J. Mccormack,et al. Ranolazine: a novel metabolic modulator for the treatment of angina. , 1998, General pharmacology.
[12] J. Mccormack,et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. , 1996, Circulation.
[13] U. Hacksell,et al. Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-Triazole-Derived Dipeptidomimetics , 1995 .
[14] W. Herron,et al. The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry. , 1995, Rapid communications in mass spectrometry : RCM.
[15] B. Cannon,et al. Overview--preparation and properties of mitochondria from different sources. , 1979, Methods in enzymology.